Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial

R. Fleischmann, T. Takeuchi, D. Schlichting, W. Macias, T. Rooney, S. Gurbuz, I. Stoykov, S. Beattie, W. L. Kuo, M. Schiff, M. Dougados

研究成果: Article査読

本文言語English
ページ(範囲)A37
ジャーナルRevue du Rhumatisme (Edition Francaise)
83
DOI
出版ステータスPublished - 2016 11月 1

ASJC Scopus subject areas

  • リウマチ学

引用スタイル